Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Mason

Nurse Practitioner Bedford, TX Nurse Practitioner

NPI 1790940807 CMS profile 11224410

3030 Harwood Rd Ste 100, Bedford, TX 76021

Open in the dashboard

General payments

$25,561

1,303 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Mason of Bedford, TX is reported in the CMS Open Payments database as having received $25,561 across 1,303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,070 227
2024 General $5,089 262
2023 General $6,778 295
2022 General $3,998 232
2021 General $4,627 287

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Mason
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jessica Mason were reported at $5,070. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jessica Mason Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,627 $135 $40–$426 $132
2022 $3,998 $152 $48–$470 $149
2023 $6,778 $166 $54–$529 $160
2024 $5,089 $173 $55–$556 $164
2025 $5,070 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,003 172 payments
  2. LivaNova USA, Inc. $1,536 10 payments
  3. Biogen, Inc. $1,290 71 payments
  4. Teva Pharmaceuticals USA, Inc. $1,205 79 payments
  5. EMD Serono, Inc. $1,081 105 payments
  6. Inspire Medical Systems, Inc. $961 10 payments
  7. UCB, Inc. $872 40 payments
  8. Novartis Pharmaceuticals Corporation $774 63 payments
  9. Pfizer Inc. $727 43 payments
  10. Lilly USA, LLC $659 37 payments
  11. Other $13,454 673 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $23,627 1,283 payments
  2. Travel and Lodging $1,406 12 payments
  3. Education $528 8 payments
Products named General payments · program years 2021–2025
  1. BOTOX Botox Therapeutic $1,519 70 payments
  2. VNS Therapy $1,469 7 payments
  3. INSPIRE $961 10 payments
  4. TYSABRI $715 37 payments
  5. NURTEC ODT Primary Care $689 39 payments
  6. QULIPTA $673 53 payments
  7. Leqembi $671 25 payments
  8. Gamunex-C $605 26 payments
  9. BOTOX Hyperhydrosis $599 36 payments
  10. NURTEC ODT Pain $589 37 payments
  11. Other $17,254 972 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

3,624

Median for Nurse Practitioner: 389

Drug cost

$561,294

Median for Nurse Practitioner: $21,885

Branded share of claims

24.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 19 $153,931
Copaxone Glatiramer Acetate Brand 12 $70,957
Emgality Pen Galcanezumab-Gnlm Brand 54 $42,780
Aimovig Autoinjector Erenumab-Aooe Brand 53 $38,743
Nurtec Odt Rimegepant Sulfate Brand 32 $34,797
Ajovy Autoinjector Fremanezumab-Vfrm Brand 34 $31,941
Keppra Levetiracetam Brand 12 $22,612
Memantine Hcl Generic 599 $22,332
Trokendi Xr Topiramate Brand 12 $14,808
Neupro Rotigotine Brand 13 $13,976

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$535 — —
BOTOX
$514 — —
Leqembi
$335 — —
NURTEC ODT
$232 32 —
Gamunex-C
$199 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

1,303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record